Drugs / F-18 Fluoroestradiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03065712 | Feb 2017 → Feb 2020 | breast cancer | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 Fluoroestradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03065712 ↗ |
| Known as | [F-18]FES | “Drug: [F-18] fluoroestradiol: [F-18]FES” NCT03065712 ↗ |
| Modality | Diagnostic / imaging agent | “F-18 Fluoroestradiol will be administered for PET/CT scan.” NCT03065712 ↗ |
| Route | Intravenous | “The patient will have an intravenous line placed typically in the hand or arm opposite to the known primary breast cancer, FES will be given by 2 minute infusion, and the dose...” NCT03065712 ↗ |